Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study

<p><strong>Background</strong> Gemcitabine is used to treat a wide range of tumours but its efficacy is limited by cancer cell resistance mechanisms. NUC-1031, a phosphoramidate modification of gemcitabine, is the first anti-cancer ProTide to enter the clinic and is designed to ove...

Full description

Bibliographic Details
Main Authors:	Blagden, SP, Rizzuto, I, Suppiah, P, O'Shea, D, Patel, M, Spiers, L, Sukumaran, A, Bharwani, N, Rockal, A, Gabra, H, El-Bahrawy, M, Wasan, H, Leonard1, R, Habib, N, Ghazaly, E
Format:	Journal article
Published:	Nature Publishing Group 2018

Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study

Similar Items